Halozyme Therapeutics, Inc. (HALO) Up 6.1% — Is This Pullback My Chance?
Halozyme Therapeutics, Inc. (HALO) is pushing decisively higher this Wednesday, last changing hands at $116.30 on the NASDAQ, a $6.68 gain from the prior close of $109.62. The advance carries the stock to within roughly 0.5% of its 52-week high of $116.85, set on September 23, 2026. Halozyme is now pressing against that level with real momentum behind it, a sign of how firmly investors have embraced the company's royalty growth story over the past year.
Volume stands at approximately 1.45 million shares so far in the session, compared with a 90-day average of about 2.09 million. With the regular session still open, the stock has already gained more than 6% on turnover running below its typical full-day pace.
Why Halozyme Therapeutics, Inc. Price is Moving Higher
The clearest catalyst is a fresh vote of confidence from Wall Street. On October 13, TD Cowen reiterated its Buy rating on Halozyme and raised its price target to $130 from $105, citing a stronger outlook for life-science tools and biotech. The new target implies meaningful upside even after today's run. The move is also distinctly company-specific. The iShares Biotechnology ETF (IBB) was up about 1.5% intraday, and large-cap Health Care names such as Eli Lilly and Company (LLY, +4.10%) and AbbVie Inc. (ABBV, +3.47%) are trading firmly higher. HALO's 6.09% gain outpaces all of them, which points to a re-rating of Halozyme itself rather than a stock lifted only by a strong tape.
TD Cowen's upgrade lands on top of a run of favorable developments for the ENHANZE franchise. On October 7, a Dutch court found that Merck (MRK) infringed a Halozyme patent and ordered it to stop making or selling subcutaneous Keytruda in eight European markets. The ruling strengthens Halozyme's intellectual property position around subcutaneous delivery of blockbuster biologics. One day later, on October 8, the FDA approved Roche's ENHANZE-enabled Tecentriq Hybreza with chemotherapy for certain patients with stage III colon cancer. The approval opens an additional royalty stream as Roche's subcutaneous checkpoint inhibitor moves into an earlier-stage, curative-intent setting.
The fundamental foundation for this rally was laid in August. Halozyme's Q2 report on August 6 delivered non-GAAP EPS of $2.28 against the $1.79 consensus. Revenue reached $481 million versus the $402.28 million expected, a 47.7% year-over-year increase. Net income climbed to $229.9 million from $165.2 million a year earlier. Management followed the beat by raising full-year 2026 revenue guidance to $1.835 billion to $1.910 billion, up from $1.710 billion to $1.810 billion. EPS guidance rose to $8.65 to $9.00 from $7.75 to $8.25. A beat of that size, paired with a guidance hike of that scale, gives TD Cowen's higher target a solid earnings base to build on.
What is the Halozyme Therapeutics, Inc. Rating - Should I Buy?
Weiss Ratings assigns HALO a B rating. Current recommendation is Buy. The rating reflects a business firing on nearly every cylinder: accelerating revenue, exceptional profitability, a balance sheet that supports aggressive capital deployment, and a stock that has rewarded holders handsomely.
Four of Halozyme's five sub-indices are rated Excellent, a breadth of strength that few companies can match. The Excellent Growth Index rating is anchored by 47.67% revenue growth, a remarkable pace for a company of this size, and it comes from royalty streams tied to some of the best-selling biologics in oncology and immunology rather than a single product launch. That same royalty structure explains the Excellent Efficiency Index rating. A 24.85% profit margin and a 173.67% ROE show how little capital Halozyme needs to grow once a partner's ENHANZE-enabled drug reaches the market. The ROE is amplified by a compact equity base, but the earnings power behind it is real. The Excellent rating on the Solvency Index indicates the company can keep funding acquisitions, patent enforcement, and shareholder returns without straining its finances. Shareholders have felt the results directly, and the Excellent Total Return Index rating is borne out by a stock now trading within a whisker of its $116.85 52-week high.
Where the picture becomes more nuanced is the Volatility Index, rated Fair. A 6% single-session jump driven by an analyst target increase illustrates the issue. Halozyme's share price reacts sharply to legal rulings, partner approvals, and Street revisions, and that sensitivity cuts both ways. This is the main factor holding the overall rating at B rather than pushing it into the A range. For investors focused on the underlying business, however, the Fair rating reflects the price of owning a high-growth royalty story more than any weakness in fundamentals.
Within the Health Care sector, Halozyme sits alongside Eli Lilly and Company (LLY, B) and AbbVie Inc. (ABBV, B), and ahead of Thermo Fisher Scientific Inc. (TMO, B-). It trails Johnson & Johnson (JNJ, B+) and Amgen Inc. (AMGN, B+) by a single notch. Keeping pace with pharmaceutical giants many times its size is a strong statement about the quality of Halozyme's business model.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) is a Health Care company headquartered in San Diego, California. Its core asset is ENHANZE, a drug delivery technology built on its proprietary recombinant human hyaluronidase enzyme, rHuPH20. The enzyme temporarily breaks down hyaluronan beneath the skin, allowing large-volume biologics that would normally require lengthy intravenous infusions to be given as subcutaneous injections in minutes. The result is a more convenient experience for patients, less chair time for infusion centers, and a lifecycle-extension tool for drugmakers protecting major franchises.
Halozyme monetizes ENHANZE by licensing it to pharmaceutical partners in exchange for upfront fees, milestone payments, and royalties on product sales. The partner roster includes some of the largest names in the industry. Johnson & Johnson's Darzalex Faspro for multiple myeloma is a flagship royalty contributor. Roche markets several ENHANZE-enabled therapies, including Phesgo for HER2-positive breast cancer, Tecentriq Hybreza, and Ocrevus Zunovo for multiple sclerosis. Other partnered products include Bristol Myers Squibb's Opdivo Qvantig, argenx's Vyvgart Hytrulo, and Takeda's HyQvia. Beyond ENHANZE, Halozyme owns specialty auto-injector technology and commercial products through its acquisition of Antares Pharma, which broadens its device and drug delivery capabilities.
Halozyme's competitive advantage rests on its patent estate, a long record of regulatory approvals across multiple therapeutic areas, and deep partner relationships that make ENHANZE a proven choice when drugmakers move blockbuster biologics to subcutaneous formulations. The company has shown it will defend that position aggressively, as its patent litigation against rival subcutaneous approaches demonstrates. Because royalties scale with partner sales while Halozyme bears little of the commercial cost, each new approval and indication expansion feeds directly into high-margin revenue.
Investor Outlook
Halozyme Therapeutics, Inc. (HALO) carries a Weiss Rating of B (Buy), backed by explosive revenue growth, a raised 2026 outlook, and a widening set of ENHANZE royalty opportunities. Investors should watch whether the stock can break cleanly above its $116.85 52-week high and how the enforcement of the Dutch Keytruda ruling unfolds across Europe. The next earnings report will show whether Halozyme is tracking toward the upper end of its $1.835 billion to $1.910 billion revenue guidance. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--